1 min read
SCOPE: Powering the Future of Clinical Research
Meet Veristat at SCOPE: Powering the Future of Clinical Research February 2-5, 2026
🔬 Advancing Clinical Research with...
2 min read
Developing advanced therapies for neurology is often described as a “perfect storm of complexity.” These studies face scientific, operational, and ethical challenges that require careful planning from the earliest stages.
Challenges Unique to Neurology Studies
Endpoints and Rating Scales
Neurology trials frequently rely on clinical rating scales rather than hard clinical endpoints, which introduces subjectivity from patients and assessors. Ensuring standardized training and consistent administration across sites is essential to reduce variability that could obscure treatment effects.
Biomarkers as Surrogates
Because many neurological diseases progress slowly, biomarkers are often explored as surrogate endpoints. Acceptance depends on context and evidence; for example, the FDA converted lecanemab for Alzheimer’s disease from accelerated to traditional approval after a confirmatory trial verified clinical benefit, underscoring that surrogate measures must ultimately link to clinical outcomes.
Delivery to the Brain
Some therapies require direct CNS delivery (e.g., stereotactic approaches or convection-enhanced delivery), sometimes involving novel devices or adaptations of surgical techniques—adding procedural variability that must be tightly controlled.
Slow Disease Progression
Conditions such as Alzheimer’s can evolve over years. Detecting meaningful differences within feasible trial timelines is challenging, which often pushes sponsors to enrich populations, optimize endpoints, or adopt innovative trial designs.
Key Considerations for Success
Manufacturing and Supply Chain
Any required manufacturing planning should begin early in development. Autologous, ex vivo cell therapies generally require a scale-out approach, producing multiple parallel batches, whereas many in vivo gene therapies rely on scale-up—increasing batch size as programs advance. Regardless of the strategy, regulators expect robust product comparability when manufacturing processes evolve. By the pivotal phase, the clinical material should closely match the intended commercial product to avoid bridging studies. Because specialized materials and components are often limited in availability, proactive supply-chain planning is equally essential.
Preclinical Studies
Before first-in-human studies, programs should characterize biodistribution, persistence, clearance, expression, and toxicity using appropriate species (from transgenic rodents to larger animals, including NHPs when justified). The FDA’s gene therapy guidance for neurodegenerative diseases emphasizes aligning models, dosing, and endpoints with regulatory expectations.
Study Design and Patient Populations
When effective treatments exist, a randomized concurrent control may be required; add-on designs to standard of care are common. Regulators will consider externally controlled (historical/synthetic) comparisons only in specific circumstances with rigorous methodology—FDA provides detailed recommendations and cautions; EMA is also actively framing its position. Concurrent, well-controlled comparisons remain the default.
Putting Patients at the Center
Patient advocacy groups (e.g., in Alzheimer’s, Huntington’s, Parkinson’s) bring crucial insights on meaningful outcomes and participant burden (multiple scales, frequent visits, caregiver time). Limiting assessments to those necessary and spacing them appropriately can reduce dropout and improve data quality.
Additional Safety and Dose Considerations
Early-phase, careful dose-finding is essential for gene therapies. While gene therapy may not reverse established neurodegeneration, earlier intervention could help stabilize or slow decline in some settings; however, detecting change in early disease can be difficult, whereas late-stage patients may decline faster but have less potential for benefit. Immune responses to viral vectors (including AAV) can affect safety and efficacy in the CNS—“immune privilege” is limited; innate and adaptive responses (e.g., microglial activation, neutralizing antibodies) have been observed and must be monitored and mitigated.
Driving Success in Advanced Neurology Studies
Neurology studies present some of the most complex challenges in clinical development—from uncertain endpoints and specialized delivery methods to long disease timelines and significant patient burden. Success depends on early planning across manufacturing, preclinical strategy, study design, and patient engagement, aligned with evolving regulatory expectations. U.S. Food and Drug Administration+1
At Veristat, we have guided advanced therapy programs across neurology, including trials in neurodegenerative diseases and other neurological conditions. Our teams combine regulatory, scientific, and operational expertise to help sponsors anticipate obstacles and move their therapies forward with confidence.
If you are preparing to advance a neurology therapy, connect with us to design, execute, and deliver studies that bring life-changing treatments closer to patients.
Contact us today to learn how we can help.
